Refresh Relieva is a Ophthalmic Solution/ Drops in the Human Otc Drug category. It is labeled and distributed by Allergan, Inc.. The primary component is Carboxymethylcellulose Sodium; Glycerin.
Product ID | 0023-6630_8e0f8349-7be7-4055-970f-3af4ff2ae82c |
NDC | 0023-6630 |
Product Type | Human Otc Drug |
Proprietary Name | Refresh Relieva |
Generic Name | Carboxymethylcellulose Sodium, Glycerin |
Dosage Form | Solution/ Drops |
Route of Administration | OPHTHALMIC |
Marketing Start Date | 2019-07-22 |
Marketing Category | OTC MONOGRAPH FINAL / OTC MONOGRAPH FINAL |
Application Number | part349 |
Labeler Name | Allergan, Inc. |
Substance Name | CARBOXYMETHYLCELLULOSE SODIUM; GLYCERIN |
Active Ingredient Strength | 5 mg/mL; mg/mL |
Pharm Classes | Allergens [CS], Cell-mediated Immunity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased IgG Production [PE], Non-Standardized Chemical Allergen [EPC] |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2019-07-22 |
NDC Exclude Flag | N |
Sample Package? | Y |
Marketing Category | OTC MONOGRAPH FINAL |
Application Number | part349 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2019-07-22 |
Marketing Category | OTC MONOGRAPH FINAL |
Application Number | part349 |
Product Type | HUMAN OTC DRUG |
Billing Unit | ML |
Marketing Start Date | 2019-07-22 |
Ingredient | Strength |
---|---|
CARBOXYMETHYLCELLULOSE SODIUM | 5 mg/mL |
SPL SET ID: | 6b984fa2-4187-45ef-b7d3-15e720abc667 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
0023-6630 | Refresh Relieva | Carboxymethylcellulose sodium, Glycerin |
63868-969 | QUALITY CHOICE LUBRICATING EYE DROPS | CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN |
0023-3416 | Refresh Optive | Carboxymethylcellulose Sodium, Glycerin |
0023-4607 | Refresh Repair | Carboxymethylcellulose sodium, Glycerin |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
REFRESH RELIEVA 88467059 not registered Live/Pending |
Allergan, Inc. 2019-06-10 |